COMMUNIQUÉS West-GlobeNewswire
-
MannKind Restructures $79.7 Million Debt Obligation to the Mann Group and Reduces Principal Owed to Deerfield by $6.3 Million
12/03/2018 - 13:08 -
Matinas BioPharma to Host 2017 Financial Results and Corporate Update Conference Call and Webcast
12/03/2018 - 13:05 -
Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast
12/03/2018 - 13:03 -
Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results
12/03/2018 - 13:00 -
Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update
12/03/2018 - 13:00 -
Krystal Biotech Reports 2017 Financial Results and Business Progress
12/03/2018 - 13:00 -
Celsion Corporation to Present at Upcoming Investor Conferences
12/03/2018 - 13:00 -
Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights
12/03/2018 - 13:00 -
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018
12/03/2018 - 13:00 -
Mersana Appoints David A. Spellman as Chief Financial Officer
12/03/2018 - 13:00 -
Global Blood Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
12/03/2018 - 13:00 -
Delcath to Present at 30th Annual Roth Conference
12/03/2018 - 13:00 -
Rockwell Medical Schedules Year End 2017 Earnings Call
12/03/2018 - 13:00 -
Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura
12/03/2018 - 13:00 -
Extendicare Announces Appointment of Michael Guerriere to Board of Directors
12/03/2018 - 13:00 -
India Globalization Capital Appoints Carrolee Barlow, MD, PhD as Advisor to Help Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD)
12/03/2018 - 13:00 -
Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive
12/03/2018 - 13:00 -
Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma
12/03/2018 - 13:00 -
Epizyme to Participate in Oppenheimer & Co. 28th Annual Healthcare Conference
12/03/2018 - 11:30
Pages